-
IntoCell signed a Material Transfer Agreemen t (or MTA) with option to license with ADC Therapeutics SA ( NYSE: ADCT ).
-
Under the agreement, IntoCell, a South Korean biotech developing novel antibody drug conjugate platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate system and payload modification technology.
-
"We are pleased to be collaborating with ADC Therapeutics, one of the leading companies in the ADC area. We hope to leverage ADC Therapeutics' experience with the development and commercialization of its own ADC ZYNLONTA. IntoCell's linker is highly stable and soluble, and our modified payload has the potential to substantially improve the therapeutic window of various payload classes. We are excited to see how our drug-linker technologies will perform with ADC Therapeutics' antibodies." said Tae Kyo Park, Founder and CEO of IntoCell.
For further details see:
IntoCell enters development and license option agreement with ADC Therapeutics